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Abstract
Background: Although the relationship between serum uric acid (SUA) and adiposity is well established, the direction of the
causality is still unclear in the presence of conflicting evidences. We used a bidirectional Mendelian randomization approach
to explore the nature and direction of causality between SUA and adiposity in a population-based study of Caucasians aged
35 to 75 years.
Methods and Findings: We used, as instrumental variables, rs6855911 within the SUA gene SLC2A9 in one direction, and
combinations of SNPs within the adiposity genes FTO, MC4R and TMEM18 in the other direction. Adiposity markers included
weight, body mass index, waist circumference and fat mass. We applied a two-stage least squares regression: a regression of
SUA/adiposity markers on our instruments in the first stage and a regression of the response of interest on the fitted values
from the first stage regression in the second stage. SUA explained by the SLC2A9 instrument was not associated to fat mass
(regression coefficient [95% confidence interval]: 0.05 [20.10, 0.19] for fat mass) contrasting with the ordinary least square
estimate (0.37 [0.34, 0.40]). By contrast, fat mass explained by genetic variants of the FTO, MC4R and TMEM18 genes was
positively and significantly associated to SUA (0.31 [0.01, 0.62]), similar to the ordinary least square estimate (0.27 [0.25,
0.29]). Results were similar for the other adiposity markers.
Conclusions: Using a bidirectional Mendelian randomization approach in adult Caucasians, our findings suggest that
elevated SUA is a consequence rather than a cause of adiposity.
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Introduction
High serum uric acid (SUA) is known to co-exist with the
components of metabolic syndrome including obesity [1–3].
Epidemiological studies found positive associations between SUA
and different adiposity markers including waist circumference [4],
body mass index (BMI) [4], waist-to-hip ratio [5] and body fat
[6,7]. Although the relationship between SUA and adiposity
appears to be well-established in conventional observational
analysis, it is difficult to ascertain if these associations are truly
causal or are a consequence of bias or residual confounding.
Further, the relationship between SUA and adiposity is compli-
cated by evidence suggesting the possibility of causality in both
directions.
Some hypothesized that SUA mediates obesity and other
features of metabolic syndrome by reducing endothelial nitric
oxide and decreasing insulin-mediated glucose uptake in skeletal
muscle [8]. Several pieces of evidence are in line with this direction
of causality. In longitudinal epidemiologic studies, baseline SUA
independently predicted weight gain [9], the development of
impaired fasting glucose [10] or incident type 2 diabetes [10–13],
even in the absence of metabolic syndrome [13] or obesity [9,10]
at baseline. Analogously, baseline hyperuricemia independently
predicted 9-year incident hyperinsulinemia in the ARIC cohort
[14], which suggests that hyperuricemia is not merely the
consequence of hyperinsulinemia. Baseline hyperuricemia was
also an independent predictor of 5-year incident metabolic
syndrome in a population-based sample in Portugal [15].
Experimental studies have shown that allopurinol, a xanthine
oxidase inhibitor that inhibits SUA synthesis, was able to prevent
weight gain in fructose-fed rats [16]. Similarly, rats administered
uricase inhibitors to induce hyperuricemia, developed features of
the metabolic syndrome [17].
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Conversely, others suggest that hyperinsulinemia (along with
accompanying obesity) reduces urinary uric acid clearance with
subsequent elevation of SUA levels [18,19]. Also, the fact that a
genetic risk score robustly associated with SUA was not associated
with fasting glucose or insulin levels in the CHARGE consortium
speaks against a causal role of uric acid on hyperinsulinemia [20].
Longitudinal epidemiologic studies found baseline BMI [21] or
weight gain [22] to predict the development of hyperuricemia
during follow-up. Furthermore, weight loss is known to lower SUA
levels [23–25], which suggests that adiposity leads to hyperurice-
mia. Hence, further investigations to clarify the nature and
direction of the causal link between SUA and adiposity are
necessary.
As far as we are aware, the relationship between SUA and
adiposity has not been previously explored using the principles of
Mendelian randomization, a method that allows disentangling
causation from association in the presence of confounding [26]. In
a large population-based CoLaus study of Caucasians, we used
SUA and adiposity-related genetic variants as instruments in a
bidirectional Mendelian randomization approach to explore the
links between SUA and adiposity. We performed a Mendelian
randomization analysis to determine 1) if adiposity markers such as
increased weight, BMI, waist circumference or fat mass are a
consequence of elevated SUA or 2) if adiposity leads to
hyperuricemia.
SUA is known to have a high (25 to 70%) heritability [27] and
recent genome-wide association studies have identified SLC2A9 to
have a strong association with SUA levels [28,29], explaining
about 1.2–6.0% of the variance in SUA concentration [30].
Amongst the adiposity-related genetic variants, we chose single
nucleotide polymorphisms (SNPs) within the most common major
adiposity genes FTO, MC4R and TMEM18, all of which have been
recognized to be associated with obesity and explaining a variance
of about 1–2% [31].
Materials and Methods
Study Population
The CoLaus study is a cross-sectional population-based study
conducted in Lausanne, Switzerland. Details of the study have
been previously described [32]. Briefly, a simple, non-stratified
random sample of 19,830 participants, corresponding to 35% of
the source population, was drawn, of which 6184 participants were
included. Inclusion criteria included a written informed consent,
age between 35–75 years and being of Caucasian origin. The
study was approved by the Ethics Committee of the University of
Lausanne. Recruitment began in June 2003 and ended in May
2006.
Study Procedure and Measurements
Participants attended the outpatient clinic at Centre Hospitalier
Universitaire Vaudois (CHUV) in the morning after an overnight
fast. They were asked to continue taking their medication as usual.
This examination included detailed questionnaire, physical
examination with anthropometric measures by trained and
certified field interviewers and laboratory testing. In the present
analysis, smoking was defined as present if the participant reported
to be current smoker at the time of examination and alcohol
consumption was defined as present for participants who report
drinking alcohol at least once a day. Diuretic use was assessed by
recording all the prescribed drugs taken by the participants and
was considered as present if participants were using drugs
belonging to any class of diuretics. Height was measured to the
nearest 5 mm using a SecaH height gauge (Hamburg, Germany),
and weight was measured to the nearest 0.1 kg using a SecaH scale
(Hamburg, Germany). These instruments were calibrated regu-
larly. Body mass index was defined as weight divided by height in
meter squared. Waist circumference was measured with a non-
stretchable tape and the mean of two measurements expressed in
centimeters was used for the analyses. Fat mass (in percent of the
total body weight) was assessed by electrical bioimpedance using
the BodystatH 1500 analyzer (Isle of Man, British Isles). Fat mass
(in kilograms) was calculated from the percentage of fat mass
multiplied by weight.
Venous blood samples were collected after an overnight fasting.
Most clinical assays were performed by the CHUV Clinical
Laboratory on fresh blood samples. Serum creatinine was
measured by Jaffe kinetic compensated method (2.9%21.5%
maximum inter and intra-batch coefficients of variation) and uric
acid by uricase-PAP (1.0%20.5%). Glomerular filtration rate
(GFR) was estimated using the abbreviated Modification of the
Diet in Renal Disease (MDRD) formula: 1866(serum creatinine
[mmol/L]/88.4)(21.154)6age(20.203)6F, where F= 1 for men and
F= 0.742 for women [33].
Genotyping
Nuclear DNA was extracted from whole blood for whole
genome scan analysis. Genotyping was performed using Affyme-
trix 500 K SNP chip, as recommended by the manufacturer
(Affymetrix, Inc., Santa Clara, California, USA). Persons with less
than 95% genotyping efficiency overall (or ,90% efficiency on
either array; n = 399) and persons with possible gender inconsis-
tencies (n = 5) were removed. Monomorphic SNPs, SNPs with less
than 70% genotyping efficiency, SNPs with minor allele frequency
less than 1%, and/or not in the Hardy-Weinberg proportions were
excluded. A hundred and twenty-nine, 20, 56 and 124 SNPs,
100 kb upstream and downstream of the FTO, MC4R, TMEM18
and SLC2A9 genes respectively, were considered for the present
analyses.
Statistical Analysis
All tests were performed using Stata 11 (StataCorp, College
Station, TX, USA). Continuous variables were summarized as
mean (standard deviation [SD]) while categorical variables as
number of subjects and percentages. We used t test and x2 test to
compare the distribution of covariates according to sex.
Pearson’s partial correlation coefficient test was used to estimate
the correlation of SUA with adiposity markers and Fischer’s Z
transformation to compare the correlation coefficients between
men and women. We performed a bidirectional Mendelian
randomization to 1) assess the causality in the direction of SUA
causing elevated adiposity and 2) reverse causality i.e. elevated
adiposity levels leading to hyperuricemia. In the former, we chose
as instrumental variable the SNP with the best F-statistics (Table 1)
from the linear regressions between the SNPs within and around
the SLC2A9 gene and SUA level, in the overall sample and
separately by sex. We identified rs6855911, rs7442295 and
rs7669607 as the best SNP in the overall sample, men and women
respectively. These variants have been identified to be related to
SUA in earlier studies [34,35]. In the latter case, using the SNPs
within and around the FTO, MC4R and TMEM18 genes
separately did not result in strong instruments. To identify
sufficiently strong instruments (i.e. an F-statistics .10) [36], we
carried out a systematic combination of three SNPs from the three
genes separately for each adiposity traits in the overall sample and
also by sex. Combinations of four SNPs from the adiposity genes
did not lead to significantly better instruments. Based on the
genotypes of FTO, MC4R and TMEM18, a score was created for
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every individual SNP, coded as 0-homozygote for the non-risk
allele, 1-heterozygote and 2-homozygote for the risk allele. When
combining the SNPs, we summed up their scores using an additive
coding for the number of alleles associated with higher adiposity
levels. This resulted in an ordinal variable with seven categories
coded from 0 to 6. Further, we present the distribution of SUA
across genotypes of the SLC2A9 rs6855911 and adiposity markers
across adiposity-related SNPs individually or as genetic scores in
the overall sample to see how the specific SNPs relate to the
phenotype of interest in the CoLaus participants and used a non-
parametric test to assess for trend. In the latter case when using
genetic scores to check for trends, we combined participants
having scores of 0, 1 and 2 since the number of participants in
these categories was small. We also reported the associations of
SNP/SNP scores with markers in the hypothesized pathway (i.e.
SLC2A9 rs6855911 with adiposity markers and adiposity-related
genetic variants with SUA).
To explore the potential causal effect in both directions, we
applied a Mendelian randomization approach, also called two-
stage least squares (2 SLS) regression, using the instrumental
variables that we identified. In the first stage, we conducted an
ordinary least square (OLS) regression, regressing SUA/adiposity
markers on our instruments (see Table 1 for the choices of
instruments in our context). In the second stage, we performed
regression of the response of interest (e.g. SUA, BMI, weight etc.)
on the fitted values from the first stage regression, which will be
referred to as ‘‘explained’’ SUA/adiposity from here on. We
conducted the above analysis using the ivregress function in Stata
11. To meet the assumptions for linear regression, we used the
most appropriate transformations for both the dependent and
independent variables (weight and waist: log transformation; SUA
and fat mass: square root transformation; and BMI: inverse square
root transformation). Further, to facilitate comparability between
the coefficients and ease interpretation of the results, both the
transformed dependent and independent variables were standard-
ized and results from regression models expressed as 1 SD change
in the outcome corresponding to a 1 SD increase in exposure (note
that the significance of the results would remain the same without
standardization). We tested for interaction by sex using the sex-
specific results from the second stage and the following test
statistic: (bmen-bwomen )/! (S.Emen
2+S.Ewomen2) where b and S.E is
the standardized beta coefficient and standard error respectively.
Provided that the assumptions underlying Mendelian random-
ization are fulfilled, the regression coefficient obtained in the
second stage can be interpreted as being the causal effect of the
‘‘explained’’ variable on the response of interest [37]. The first
assumption (i.e. the instrument is correlated with the explained
SUA/adiposity), is usually considered to be met if the F-statistics
calculated in the first stage regression is greater than 10 [36],
which is true in our context. We could partly check the second
assumption (i.e. the instrument is unrelated to the confounders) by
examining the association between the instruments and the
potential confounders (as below) that were measured, as done by
others [38,39]. We found none of the measured confounders to be
significantly associated with the instruments. The third assumption
(i.e. the instrument has an effect on the response of interest solely
via the explained variable), is difficult to verify from the data. We
compared the estimates from the OLS and 2 SLS using the
Durbin-Hausman test. This process was repeated for each
association of interest in the overall sample and in the sex strata.
We conducted both unadjusted and adjusted analyses controlling
for age, sex, smoking, alcohol use, GFR and diuretic use,
covariates which can potentially influence the associations between
SUA and adiposity markers. To address the possibility of
confounding by population stratification, we included principal
components generated from genome-wide SNPs data as covariates
to the analysis. The significance level used for two-sided tests was
P,0.05.
Table 1. Association between SNPs chosen as instruments and intermediate phenotype.
Gene combination F-statistics R2
SNP SNP SNP
Combined SNPs (instruments) within/around FTO, MC4R and TMEM18 for adiposity markers
BMI Overall FTO rs1121980 FTO rs2665272 TMEM18 rs6755502 27.06 0.0052
Men FTO rs7193144 FTO rs6499658 TMEM18 rs2683992 17.59 0.0072
Women FTO rs2540769 FTO rs2665272 TMEM18 rs2860323 21.25 0.0083
Fat mass Overall FTO rs7193144 FTO rs17823223 TMEM18 rs10189761 28.45 0.0052
Men FTO rs7193144 FTO rs16945088 FTO rs17823223 20.73 0.0081
Women FTO rs1121980 FTO rs17823223 TMEM18 rs7585056 21.50 0.0076
WC Overall FTO rs1861868 FTO rs8050136 TMEM18 rs6755502 36.69 0.0070
Men FTO rs8050136 FTO rs8053740 MC4R rs17066829 15.87 0.0061
Women FTO rs1121980 FTO rs2665272 TMEM18 rs7571872 31.20 0.0124
Weight Overall FTO rs1121980 FTO rs17823223 TMEM18 rs6755502 31.43 0.0060
Men FTO rs7193144 FTO rs17823223 FTO rs2192872 16.56 0.0060
Women FTO rs9939973 FTO rs836994 TMEM18 rs6755502 21.93 0.0080
SNPs (instruments) within/around SLC2A9 for SUA
SUA Overall SLC2A9 rs6855911 170.47 0.0316
Men SLC2A9 rs7442295 71.49 0.0265
Women SLC2A9 rs7669607 197.21 0.0626
BMI = body mass index; WC=waist circumference; SUA= serum uric acid; SNP = single-nucleotide polymorphism.
doi:10.1371/journal.pone.0039321.t001
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Results
Table 1 summarizes the combinations that produced the best
instrument for the different adiposity traits in the overall sample
and by sex. Significant linear trends (either increasing or
decreasing) were observed for the distribution of the phenotypes
of interest across their respective genotypes or genetic scores (in the
case of combined adiposity-related genetic variants) (Tables S1
and S2). Similar significant linear trends of SUA across genetic
scores of adiposity-related genetic variants were noted (Table S3)
but not for the distribution of adiposity markers across genotypes
of SLC2A9 rs6855911 (Table S4).
Of the 6184 participants, the range of missing genetic
information varied across the different SNPs (chosen as instru-
ments) of the SLC2A9 and adiposity-related genes: FTO (range of
missing data: 557–695), MC4R (748), TMEM18 (650–1442) and
SLC2A9 (590–963). No significant difference with regards to the
phenotype of interest i.e. adiposity markers and SUA was noted
between participants with and without missing genetic data. Data
was also missing for the adiposity markers: weight (n = 9), body
mass index (n= 9), waist circumference (n = 9) and fat mass
(n = 64).
The main demographic and clinical characteristics of CoLaus
participants according to sex are summarized in Table 2. Men
were slightly younger than women with a mean (SD) age of 52.6
(10.8) years vs. 53.5 (10.7) years. SUA was significantly higher in
men (361 (75.7) mmol/L) than in women (270.6 (67.2) mmol/L) as
well as the prevalence of reported alcohol consumption and
smoking. With regards to adiposity, men had significantly higher
weight, BMI and waist circumference (P,0.001 in all) while
women had higher fat mass (P,0.001).
Table 3 displays the partial Pearson’s correlation coefficients of
SUA with the selected anthropometric phenotypes, separately for
men and women. SUA showed significant positive correlations
with all traits (P,0.001). The correlations were stronger in women
than in men for weight (r = 0.33 vs. r = 0.24, P for sex difference
,0.001), BMI (r = 0.35 vs. r = 0.28, P=0.002), waist circumfer-
ence (r = 0.36 vs. r = 0.29, P= 0.001), and fat mass (r = 0.35 vs.
r = 0.27, P,0.001).
We did not find any associations of the genetic variants with the
other measured confounders (Table S5), thereby verifying to some
extent that the instruments were independent of the measured
confounders, which is an indication of the validity of the
instruments.
The statistics from the first-stage regression between SLC2A9
SNPs used as instruments and SUA presented sufficient F-statistic
values (F = 170.47, 71.49 and 197.21 for rs6855911 in overall
sample, rs7442295 in men and rs7669607 in women respectively,
Table 1). Table 4 shows the associations between SUA explained
by rs6855911 and the selected markers of adiposity (as dependent
variables) in the overall sample. Both crude and adjusted analyses
showed significant positive associations between SUA and all the
selected adiposity markers (P,0.001) in the OLS regression.
However, in the 2 SLS regression using instrumental variables, we
observed no significant association with the adiposity traits. The
results obtained from 2 SLS do not provide evidence of a causal
effect of SUA on adiposity markers. This is further substantiated
by the finding, in most cases, of a significant difference between
the OLS and 2 SLS standardized coefficients, as shown by the P-
value obtained from the Durbin-Hausman test. Similarly,
conducting the same analyses but using rs7442295 as instrument
in men (Table S6) and rs7669607 as instrument in women (Table
S7) resulted in similar conclusions, with the standardized
coefficients derived from 2 SLS being close to zero for all the
adiposity traits.
For the relationship between SUA and adiposity markers in the
reverse direction, where SUA was used as the dependent variable,
we obtained different combinations of SNPs that produced large
enough F-statistics for the different adiposity traits separately in the
overall sample, in men and in women (Table 1). Table 5 describes
the coefficients derived from the OLS and 2 SLS regressions in the
overall sample using combinations of adiposity-related SNPs as
instrumental variables. In both crude and adjusted OLS analyses,
SUA was significantly positively associated with all the selected
adiposity markers (P,0.001) in the overall sample. The associa-
tions obtained from the 2 SLS regression were similar to the OLS
regression both in magnitude (in most cases) and direction, and
remained significant in the unadjusted analyses. In fat mass, the
association was significant even after adjustment (P=0.048). Sex-
specific results are presented in Tables S8 and S9. We did not find
any evidence for an interaction by sex (i.e. estimates did not
Table 2. Demographic and clinical characteristics of CoLaus
participants.
Men (n=2,933)
Women
(n=3,251)
Mean SD Mean SD P value
Age (years) 52.6 10.8 53.5 10.7 ,0.001
Alcohol consumptiona, % 36.1 15.7 ,0.001
Current smokinga, % 29.3 25 ,0.001
Diuretic usea, % 1.7 2.8 0.003
Weight (kg) 81.5 13.3 66.4 12.9 ,0.001
BMI (kg/m2) 26.6 4.0 25.1 4.9 ,0.001
WC (cm) 95.8 11.3 83.4 12.4 ,0.001
Fat mass (kg) 19.8 7.6 23.4 9.5 ,0.001
GFR (ml/min/1.73 m2) 86.7 17.4 80.7 15.2 ,0.001
Serum uric acid
(mmol/L)
361.1 75.7 270.6 67.2 ,0.001
BMI = body mass index; GFR = estimated glomerular filtration rate (calculated
according to Modification in Diet in Renal Disease equation); WC=waist
circumference.
aResults are presented as percentages.
Between-group comparisons by t-test, Chi-square test or Wilcoxon ranksum
test.
doi:10.1371/journal.pone.0039321.t002
Table 3. Pearson’s partial correlation coefficient of adiposity
markers with serum uric acid according to sex.
Men Women
r P-value r P-value P-valuea
Weight 0.24 ,0.001 0.33 ,0.001 ,0.001
Fat mass 0.27 ,0.001 0.35 ,0.001 ,0.001
BMI 0.28 ,0.001 0.35 ,0.001 0.002
WC 0.29 ,0.001 0.36 ,0.001 0.001
BMI = body mass index; WC=waist circumference.
aP value testing the difference in correlation coefficient between men and
women.
Adjusted for age, smoking, alcohol use, estimated glomerular filtration rate
(GFR) and diuretic use.
doi:10.1371/journal.pone.0039321.t003
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significantly differ in men and in women). The direction of
association with BMI in men was reversed in the 2 SLS as opposed
to the OLS results although this did not result in a significant
difference between the two coefficients (P value from Durbin-
Hausman test = 0.671). Of interest is the observation that the
magnitude of both the crude and adjusted coefficients was very
similar in most cases, this being more apparent upon stratification
by sex. The large confidence intervals in the 2 SLS associations
reflect the relative weakness of the instruments. Controlling for
population stratification using principal components generated
from genome-wide SNPs data as covariates into the multivariable
models did not produce any relevant changes in the estimates (data
not shown).
Discussion
Using a bidirectional Mendelian randomization approach in a
population-based study of Caucasians aged 35 to 75 years, we tried
to unravel the direction of causality between SUA and adiposity
markers. SUA explained by SLC2A9 rs6855911 in the overall
sample, by rs7442295 in men or by rs7669607 in women, was not
associated with any of the selected adiposity markers; the second-
stage estimates from the instrumental variable approach were close
to zero. Thus, in the present study, we found no evidence to
Table 4. Association of SUA (using rs6855911 from the SLC2A9 gene as instrument) with adiposity measures (dependent variable
of interest) in the overall sample.
Ordinary least square (OLS) 2-stage least square (2 SLS)
N b (95% CI) P valueOLS b (95% CI) P value2SLS P value
a
Weight Crude 5224 0.51 (0.49, 0.53) ,0.001 0.06 (20.08, 0.20) 0.416 ,0.001
Adjusted 5223 0.32 (0.29, 0.35) ,0.001 0.01 (20.12, 0.14) 0.890 0.002
Fat mass Crude 5180 0.19 (0.16, 0.21) ,0.001 0.04 (20.11, 0.18) 0.630 0.042
Adjusted 5179 0.37 (0.34, 0.40) ,0.001 0.05 (20.10, 0.19) 0.521 0.004
BMI Crude 5224 0.39 (0.37, 0.42) ,0.001 0.02 (20.13, 0.16) 0.823 ,0.001
Adjusted 5223 0.40 (0.36, 0.43) ,0.001 20.01 (20.16, 0.14) 0.942 ,0.001
WC Crude 5224 0.53 (0.51, 0.56) ,0.001 0.11 (20.03, 0.25) 0.120 ,0.001
Adjusted 5223 0.36 (0.33, 0.39) ,0.001 0.08 (20.05, 0.21) 0.236 0.006
BMI = body mass index; SUA= serum uric acid; WC=waist circumference.
The b(95%CI) represents the association of SUA with adiposity markers as tested by the conventional epidemiological method (ordinary least square [OLS]) and by the
instrumental variable analysis in a two-stage least square (2 SLS) regression (so called Mendelian randomization approach whenever the instruments are genetic
variants). Similar magnitude and direction of coefficients derived from both the OLS and 2 SLS regressions suggest a causal effect of exposure (in this case SUA) on the
outcome of interest (in this case adiposity). Further, a P value2SLS ,0.05 against the null hypothesis favors a causal effect of SUA on adiposity.
aP value from the Durbin-Hausman test which compares the difference between estimates derived from the OLS and 2 SLS regressions.
Results are expressed as standardized regression coefficient (b) along with 95% confidence interval (CI).
Adjusted analysis controlled for age, sex, smoking, alcohol use, estimated glomerular filtration rate (GFR) and diuretic use.
doi:10.1371/journal.pone.0039321.t004
Table 5. Association of adiposity measures (using combined SNPs from the FTO, MC4R and TMEM18 gene as instrument) with SUA
(dependent variable of interest) in the overall sample.
Ordinary least square (OLS) 2-stage least square (2 SLS)
SNPs N b (95% CI) P valueOLS b (95% CI) P value 2 LSLP value
a
Weight FTO rs1121980+ FTO rs1782322+ TMEM18 rs6755502 Crude 5180 0.50 (0.48, 0.53) ,0.001 0.50 (0.20, 0.80) 0.001 0.947
Adjusted 5179 0.27 (0.25, 0.30) ,0.001 0.31 20.01, 0.62) 0.060 1.000
Fat mass FTO rs7193144+ FTO rs17823223+ TMEM18 rs10189761Crude 5396 0.19 (0.16, 0.21) ,0.001 0.49 (0.13, 0.84) 0.008 0.102
Adjusted 5395 0.27 (0.25, 0.29) ,0.001 0.31 (0.01, 0.62) 0.048 1.000
BMI FTO rs1121980+ FTO rs2665272+ TMEM18 rs6755502 Crude 5206 0.39 (0.36, 0.41) ,0.001 0.36 (0.04, 0.69) 0.026 0.900
Adjusted 5205 0.26 (0.24, 0.29) ,0.001 0.10 (20.22, 0.42) 0.558 0.996
WC FTO rs1861868+ FTO rs8050136+ TMEM18 rs6755502 Crude 5184 0.53 (0.51, 0.55) ,0.001 0.36 (0.09, 0.64) 0.008 0.239
Adjusted 5183 0.31 (0.28, 0.33) ,0.001 0.21 (20.09, 0.51) 0.161 0.999
BMI = body mass index; SNP = single-nucleotide polymorphism; SUA= serum uric acid; WC=waist circumference.
The b(95%CI) represents the association of SUA with adiposity markers as tested by the conventional epidemiological method (ordinary least square [OLS]) and by the
instrumental variable analysis in a two-stage least square (2 SLS) regression (so called Mendelian randomization approach whenever the instruments are genetic
variants). Similar magnitude and direction of coefficients derived from both the OLS and 2 SLS regressions suggest a causal effect of exposure (in this case adiposity) on
the outcome of interest (in this case SUA). Further, a P value2SLS ,0.05 against the null hypothesis favors a causal effect of adiposity on SUA.
aP value from the Durbin-Hausman test which compares the difference between estimates derived from the OLS and 2 SLS regressions.
Results are expressed as standardized regression coefficient (b) along with 95% confidence interval (CI).
Adjusted analysis controlled for age, sex, smoking, alcohol use, estimated glomerular filtration rate (GFR) and diuretic use.
doi:10.1371/journal.pone.0039321.t005
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suggest that SUA causally impacts on adiposity. By contrast, using
genetic variants of the FTO, MC4R and TMEM18 genes as
instruments to explain the effect of adiposity on SUA, we observed
a causal positive association of weight and fat mass with SUA in
the overall sample; the association of fat mass with SUA was
present in both men and women. This finding is not totally
unexpected and is compatible with the hypothesis that hyperin-
sulinemia, a consequence of overweight and obesity, enhances
renal proximal tubular reabsorption of uric acid with subsequent
elevation of SUA levels [18]. Our findings are compatible with a
positive causal effect of adiposity on elevated SUA. This evidence
is further supported by the observation that weight reduction leads
to a fall in plasma uric acid levels [25]. Considering that
hyperuricemia is a strong risk factor for gout [40,41], a potential
clinical implication of our results is that weight loss should
decrease, and weight gain increase, gout incidence, as recently
observed in a large prospective study [42]. However, we cannot
rule out the possibility that these findings could reflect a failure to
fulfill the assumptions underlying Mendelian randomization.
To the best of our knowledge, this is one of the few population-
based studies to use a bidirectional Mendelian randomization
approach. Welsh et al. were among the first to have demonstrated
the usefulness of a bidirectional Mendelian randomization
approach in unraveling the directional link between adiposity
and inflammation where the direction of relationship had not been
otherwise proven [43]. The technique of Mendelian randomiza-
tion might help to surmount the problems that are often
encountered in traditional observational epidemiology. The
objective of most epidemiological research is to obtain conclusions
that provide causal evidence. However, this is not always possible
because of the unintended noise in the data resulting from the
presence of known and unknown confounders, which are often
difficult to control for. In addition, there is the problem of reverse
causality as it is often difficult to determine which of the two
variables of interest is the cause and which is the effect. Genetic
variants can be thought of exposures that have been randomly
allocated at the time of gamete formation [44] and Mendelian
randomization approach as a natural randomized controlled trial
[45]. A bidirectional Mendelian randomization approach using
genetic variants, in our context where existing evidences on the
direction of causality between SUA and adiposity is conflicting and
inconclusive, is a useful method.
Recent genome-wide association studies have identified the
solute carrier (SLC) family 2, member 9 (SLC2A9) gene, encoding
a putative hexose transporter, to be strongly associated with SUA
[29,34,35,46], including the SNP most significantly associated with
SUA in this study. The SLC2A9 gene explains a substantial
proportion (about 1–6%) of variance in SUA concentration [30]
and the associations between these variants and SUA have been
consistently replicated across studies [29,34,35,46]. Vitart et al
showed that the SLC2A9 gene has urate transport activity and
found the most significant SLC2A9 SNPs for SUA to be associated
with a low fractional excretion of uric acid [29].
Conventional epidemiological studies show positive significant
associations between SUA and adiposity markers (used as outcome
variable although not clearly stated) like BMI [9,47], waist-hip
ratio [47] and body fat [6,48]. Except for Masuo et al. who
reported that SUA predicted subsequent weight gain [9], these
studies did not clearly discuss causal associations and it is not
possible to infer causality from them. The findings by Masuo et al.
and by others [10–15] are in line with previous hypothesis of a
putative causal effect of uric acid on adiposity which states that
uric acid could mediate obesity and other features of the metabolic
syndrome by reducing endothelial nitric oxide and decreasing
insulin-mediated glucose uptake in skeletal muscle [8]. However,
estimates obtained in our analysis using an instrumental variable
approach did not show an association in this direction. Consid-
ering that genetic variants are not influenced by confounding and
that the instruments used for these analyses were sufficiently
strong, our results are certainly of interest in that they provide
some evidence against a causal association in this direction.
With respect to exploring causality in the other direction, i.e.
SUA could be a consequence of excess fat accumulation, we took
advantage of the fact that obesity has a strong genetic component
with heritability estimates ranging from 65 to 80% [49].
Unfortunately, most genetic markers identified so far only explain
a very small fraction of BMI or related continuous adiposity
markers, so that we had to combine multiple instruments for this
analysis. The practice of combining variants from different genes
into an additive genetic score to improve instruments is not
uncommon [43,50,51] and has been shown to be an efficient
linear combination of individual instruments resulting in better
precision of the instrumental variable estimator. This proved
practical in order to ensure sufficiently strong instruments (as
evident by the F-statistic and R2) to fulfill the first assumption
underlying the approach. However, we acknowledge that this
practice can also lead to an increase in bias of the estimates
[52,53]. The current study focused on variants located within and
around FTO, MC4R and TMEM18 that are amongst the genes
most strongly associated with obesity traits [54] and also identified
in earlier meta-analyses [55–58], despite the fact that the variance
explained by these loci is small (1–2%) [31]. Although one can
argue that the instruments used for the associations in the direction
of adiposity causing elevated SUA are adequate but not sufficiently
strong (as illustrated by the wide confidence intervals), we observed
consistent trends with weight, fat mass and waist circumference.
The 2 SLS estimates did not deviate much from the OLS
estimates unlike what was found when we used the SLC2A9
variants as instruments.
The strengths of this study are its population-based design, the
large sample size and accessibility to detailed and relevant
information. However, our results have to be interpreted with
caution since the validity of a Mendelian randomization approach
in observational epidemiology relies partly on unverifiable
assumptions. Some of the potential sources of residual confound-
ing may arise due to pleiotropy and population stratification.
Pleiotropy of genetic variants is difficult to address without
examining all the biological pathways and this is often not possible
because of the lack of understanding on the exact underlying
mechanisms. However, we did not observe significant associations
between any of the instruments and potential confounders
suggesting that the associations are unlikely to be mediated
through biological pathway involving the measured confounders.
Similarly, it is reasonable to speculate that residual confounding
from the association between the instruments and unmeasured
confounders is minimal based on our findings of comparable crude
and adjusted estimates (particularly in the direction of adiposity
causing elevated SUA). We also did not find evidence of
confounding by population stratification in our data.
There are also other limitations in this study. First, the
adiposity-related genetic variants used as instruments were weak,
resulting in the estimates having wide confidence intervals and low
precision. Second, the approach used here is not the classical
Mendelian Randomization approach but a slight deviation from it
(which has been considered in Hernan et al [59]), since both the
SUA and adiposity-related genetic variants used as instruments are
not the direct gene products. Thus, there is always a risk that the
proteins on the pathway work as confounders and drive the
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association. Third, since we included only middle-aged Cauca-
sians, the findings may not be generalizable to other populations.
Fourth, the approach of selecting the best genetic instrument in
the CoLaus sample may be subject to over-fitting. Finally, an
important issue is that the statistical power is, in general, not the
same in both directions. In this regard, it is interesting to note that
our confidence intervals of the instrumental variable analyses were
in general wider when estimating a causal effect of adiposity on
SUA than when estimating a causal effect of SUA on adiposity
(recall that since all variables are standardized, the effects are
expressed on a similar scale, which allows such a comparison).
This means that we had more power in the direction where we
could not find a significant causal effect than in the direction
where we found some significant causal effects (this being
consistent with the fact that we had a stronger instrument in the
former direction). Thus, our non-significant causal effects of SUA
on adiposity may not only be due to a lack of power.
In conclusion, using a bidirectional Mendelian randomization
approach, our findings suggest that elevated SUA is a consequence
rather than a cause of elevated adiposity. To our knowledge, this is
the first study in which the relationship between SUA and
adiposity has been explored using genetic tools. While future
studies are essential to confirm these findings, our observations
may shed some light on the uncertainty underlying this
pathophysiological link and highlight the usefulness of the
bidirectional Mendelian randomization approach to decipher the
direction of causality.
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